HomeBUSINESS
BUSINESS

Astellas/Pfizer Amend Xtandi Trial Protocol, Topline Data Due Out This Year
(Jun.12.2017)

Astellas Pharma and Pfizer said on June 9 that they have revised the protocol of a global PIII study, dubbed PROSPER, evaluating Xtandi (enzalutamide) for non-metastatic castration-resistant prostate cancer (CRPC), with its topline data readout now expected for later this year ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 28.

News Calendar